CD8A and neoplasm: This vaccine suppresses tumor relapse via promoting the maturation of DCs and eliciting of tumor infiltration of CTLs.151 JQ1 also has the ability to restore an immune-active environment by increasing intratumor DCs and CD8C T lymphocytes, and decreasing myeloid-derived suppressor cells.34 In addition, BETi enhances the immunogenicity of prostate cancer cells and the susceptibility to CD8 T-cell targeting by increasing MHC I expression.152